KR810000612B1 - Process for preparing 2,p-dioxatricyclo(4,3,1,0 3,7)decanes - Google Patents
Process for preparing 2,p-dioxatricyclo(4,3,1,0 3,7)decanes Download PDFInfo
- Publication number
- KR810000612B1 KR810000612B1 KR7700414A KR770000414A KR810000612B1 KR 810000612 B1 KR810000612 B1 KR 810000612B1 KR 7700414 A KR7700414 A KR 7700414A KR 770000414 A KR770000414 A KR 770000414A KR 810000612 B1 KR810000612 B1 KR 810000612B1
- Authority
- KR
- South Korea
- Prior art keywords
- decane
- methoxy
- dioxatricyclo
- methyl
- beta
- Prior art date
Links
- 0 C[C@@](C(*(*)C1O)C11[O+])C2[C@]1(C)[C@](C)(*)[C@](*)C2 Chemical compound C[C@@](C(*(*)C1O)C11[O+])C2[C@]1(C)[C@](C)(*)[C@](*)C2 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
내용 없음.No content.
Description
본 발명은 2,9-디옥사트리시클로-(4,3,1,0,3,7)-데칸의 제조 방법에 관한 것이다.The invention 2,9-dioxa-tricyclo-relates to a process for the preparation of decane - (4,3,1,0, 3,7).
여러 2,9-디옥사트리시클로-(4,3,1,0,3,7)-데칸류 화합물중의 일부는 중추신경제에 완충효과(damping effect)가 있고 최면작용이 있으며 신경마비와 유사한 작용이 있고, 혈관확장 효과가 있다. 동시에 본 화합물중의 기타 일부는 명백한 진통작용이 있으며 진그로 인해 식욕부진이 있을 수 있을 수 있다.Some of the many 2,9-dioxatricyclo- (4,3,1,0 , 3,7 ) -decane compounds have a buffering effect, hypnosis, and neuropathy in the central economy. It has the effect of vasodilation. At the same time, some of the other compounds have obvious analgesic activity and can cause anorexia due to the gin.
본 발명은 유용한 약리 작용과 치료학적 성질이 있는 2,9-디옥사트리시클로-(4,3,1,0,3,7)-데칸에 관한 것이다.The present invention is useful pharmacological and therapeutic properties with 2,9-dioxa-tricyclo-decane relates to - (4,3,1,0, 3,7).
3'-위치에서 염기성 치환을 시킨 화합물은 숙면을 상당히 증가시킬뿐 아니라, 파라독살 수면(Paradoxal Sleep)을 일으킬 수 있다는 사실을 의외로 발견하게 되었다.It was surprisingly discovered that compounds with a basic substitution at the 3'-position not only significantly increased sleep but could also cause paradoxal sleep.
본 발명 화합물인 2,9-디옥사트리시클로-(4,3,1,0,3,7)-데칸의 일반식은 다음과 같다.The present invention compound is 2,9-dioxa-tricyclo (4,3,1,0, 3,7) - decane general expression as follows.
식중 R1은 제1, 제2 혹은 제3아민기이고, R2및 R3중 하나는 수소 원자이고 다른 하나는 수산기, 아실옥시 혹은 카르바모일 옥시기이며, 또는 R2및 R3는 시로 함께 산소 원자이고, R4및 R5중 하나는 수소원자이며 다른 하나는 알콕시이고, 10,11-위치는 수소첨가화 될 수 있다.Wherein R 1 is a first, second or tertiary amine group, one of R 2 and R 3 is a hydrogen atom and the other is a hydroxyl group, acyloxy or carbamoyl oxy group, or R 2 and R 3 are Together are oxygen atoms, one of R 4 and R 5 is a hydrogen atom and the other is alkoxy and the 10,11-position can be hydrogenated.
본 화합물 2,9-디옥사트리시클로-(4,3,1,0,3,7)-데칸의 가치있는 작용은 숙면 및 렘(REM)-수면에 대한 작용으로 다른 진정효과 및 독성이 적은 특징과 함께 쥐실험에서 나타난 전기 신경 전도 방법으로 이미 확립되어서 수면에 대한 최근의 연구에서 요구하는 조건을 만족시키고 있다.The valuable action of the present compound 2,9-dioxatricyclo- (4,3,1,0 , 3,7 ) -decane is its action on sleep and REM-sleep, resulting in less sedative and less toxic effects. In addition to the characteristics, the electrical nerve conduction method shown in the rat experiment has already been established to meet the requirements of recent studies on sleep.
생체의 회복에 절대로 필요한 렘(REM)-수면을 연장시킬 수 있는 수면제는 현재에는 판매되고 있는 것이 없다.There are currently no sleeping pills available that can extend REM-sleep, which is absolutely necessary for the recovery of living organisms.
본 제품의 놀라운효과는 특히 구조식(II)의 피페리디노 유도체를 고려함으로써 예시될 수 있겠다.The surprising effect of this product can be exemplified by considering the piperidino derivatives of formula (II).
구조식(II)화합물은 약리학적으로 염산염으로써, 부호 1973으로 표시된 실험으로 관찰되었고 하이드로젠 타르트레이트로써는 실험번호 제2661호로 표시된 실험으로 관찰되었다. 흰쥐를 사용하여 구조식(I)화합물을 검정하였을 때 경구로 체중 1킬로그람당 10미리그람까지의 용량, 용량의 크기에 따라서 벤조디아제핀이나 바르비트레이트에 의하여 야기될 수 있는 항경련성 효과 없이 핵소바르비탈에 유도된 수면의 기간을 연장시키는 것을 구조식(II)화합물이 유도하기 때문에 쉽게 구조식(I)화합물은 인식할 수 있었다.The compound of formula (II) was observed pharmacologically as a hydrochloride salt, in the experiment indicated by the symbol 1973, and as hydrogen tartrate, as an experiment indicated by the experiment number 2661. When the compounds of formula (I) were assayed in rats, nucleobarbital was administered orally without the anticonvulsant effect caused by benzodiazepines or barbitrate, depending on the dose or dose, up to 10 mg per kilogram of body weight. The compound of formula (I) was easily recognizable because the compound of formula (II) induced the prolongation of sleep induced by.
운동력시험에서 이같은 운동력을 저해하는 효과에 대한 ED50은 경구투여시 체중 킬로그람당 3미리그람 이었다.In the exercise test, the ED 50 for this inhibitory effect was 3 milligrams per kilogram of body weight when administered orally.
이러한 진정효과는 렛트를 대상으로 이 화합물을 검정하였을 때 확인되었다. 쥐에서 수면기간동안에 새로운 EEG효과가 확실하게 되었다. 경구로 체중 1킬로그람당 2.5내지 80미리그람의 용량으로 투여하였때 잠을 자지않는 기간의 크기는 현저한 감소 없이 렘(REM)수면 및 숙면 시기를 상당히 증가시켰다. 이 같은 효과는 4시간 및 8시간의 관찰시기에서 모두 확인되었다.This sedative effect was confirmed when the compound was assayed in rats. In mice, new EEG effects were evident during sleep. When administered orally at a dose of 2.5 to 80 milligrams per kilogram of body weight, the length of the no-sleep period significantly increased REM sleep and sleep time without a significant decrease. This effect was confirmed at both 4 and 8 hours of observation.
마우스에서 복강내로 주사시 염산염 화합물의 LD50은 406mg/kg이고 경구 투여시는 1136mg/kg이다 10,11-디히드로 형태의 구조식(IIa)화합물 구조식(III) 및 (IV)의 화합물은 구조식(V)의 몰포리노 화합물과 마찬가지로 유사한 특징을 나타낸다.The LD 50 of the hydrochloride compound when injected intraperitoneally in mice is 406 mg / kg and 1136 mg / kg when administered orally. 10,11-dihydro form of structural formula (IIa) Similar characteristics are shown as in the morpholino compound of V).
및 그와 다른 화합물은 다음 표 1에서 6까지에 열거 하였으며 이들 모든 화합물은 동일한 작용이 있음을 알 수 있다.And the other compounds are listed in the following Table 1 to 6 and all these compounds can be seen that the same action.
3'-탄소 원자에 3급 아민으로 치환된 본 발명 화합물은, 구조식(VIII)의 할로겐 화합물을 촉매존재하, 적당하기로는 용매로서 아민을 사용하거나 혹은 희석후, 디메틸포름아미드와 같은 중성 용매를 사용하여 아미노분해에 의해 생성될 수 있다. 이리하여 생성된 아민 화합물은 10,11-2중 결할을 환원하고, 4-위치의 탄소 원자에 치환제로 치환시킨 후 목적하는 염류로 전환시킬 수 있다. (실시예에서 설명될 것이다.)Compounds of the present invention substituted with tertiary amines at 3′-carbon atoms, in the presence of a catalyst of the halogen compound of the formula (VIII), suitably use an amine as a solvent or after dilution, neutral solvents such as dimethylformamide Can be produced by aminolysis. The amine compound thus produced can be reduced to 10,11-2, and converted to the desired salts by substituting a substituent on the carbon atom at the 4-position. (It will be explained in the embodiment.)
(R12=하이드록시 혹은 아세톡시(R 12 = hydroxy or acetoxy
R13=알킬 혹은 아르알킬R 13 = alkyl or aralkyl
X=옥소, 취소 혹은 염소).X = oxo, cancel or chlorine).
구조식(VI)의 제1급 아민 유도체는, 구조식(VIII)의 할라이드로부터 유래된 구조식(IX)의 아자이드를 거쳐 합성될 수 있다. 아자이드를 제1급 아민 유도체로 환원시키는 방법은 공지의 방법인 수소를 라니닉켈(Raney nickel)접촉시키거나, 혹은 하이드라진으로 환원시킬 수 있다. 구조식(X)의 제3급 벤질아민 유도체를 첨가분해성탈벤질화에 의하여 구조식(VII)의 제2급 아민 유도체가 얻어진다. 구조식(XI)의 디메틸아민 유도체는, 구조식(VI)의 제1급 아민유도체를 포름알데히드로 환원형 메틸화에 의해 생성된다.The primary amine derivative of formula (VI) can be synthesized via the azide of formula (IX) derived from the halide of formula (VIII). The method of reducing azide to a primary amine derivative may be carried out by contacting hydrogen, which is a known method, with Raney nickel, or with hydrazine. The secondary amine derivative of formula (VII) is obtained by addition-decomposable debenzylation of the tertiary benzylamine derivative of formula (X). Dimethylamine derivatives of formula (XI) are produced by formaldehyde reduction methylation of the primary amine derivative of formula (VI).
본 발명을 다음 실시예에 따라 열거하겠다.The present invention will be listed according to the following examples.
다음 표 1-6에서 표시된 선광도는, 염류인 경우는 물속에서, 유기기질인 경우는 메탄올 중에서 측정된 것이다.The luminous intensities shown in the following Table 1-6 are measured in water for salts and in methanol for organic substrates.
[실시예 1]Example 1
[구조식(VIII)의 3-요드메틸-4-아세톡시-8-메틸렌-2,9-디옥사트리시클로-(4,3,1,0,3,7)-데칸에 서부터 구조식(IIa)의 3-피페리디노메틸-4-하이드록시-4-메톡시-10-메틸렌-2,9-디옥사트리시클로-(4,3,1,0,3,7)-데칸의 제법][3-Iodomethyl-4 of Structural Formula (VIII) -Acetoxy-8-methylene -2,9- dioxa-tricyclo (4,3,1,0, 3,7) - 3-piperidino-4 seobuteo of formula (IIa) in decane -Hydroxy-4-methoxy-10-methylene -2,9- dioxa-tricyclo (4,3,1,0, 3,7) The preparation of decane;
(R12=아세톡시, R13=메틸).(R 12 = acetoxy, R 13 = methyl).
구조식(XIII)의 화합물 190g 및 중조 250g을 피페리딘 500ml에 가한다. 용액을 유욕에서 150℃로 맹렬히 교반시키면 시환류시킨 다음 실온으로 냉각한다. 혼합물에 에텔 1.5리터를 가한 후 , 물 1리터 40%가성소다를 녹인 용액을 가한다. 에텔층을 분리한다음 수층을 매회 500ml의 에텔로 추출한다. 에텔추출물을 다합하여 황산소듐상에서 건조하고 활성탄으로 깨끗이 한다. 흡인 여과기로 "네오리트"를 통하여 여과하고 에텔로 세척한다. 이액을 회전 증발기에서 농하축는데 처음에는 물 제트 펌프의 진공에서 50℃로, 다음은 100℃로 농축하면, 유상 화합물(IIa)가 180g수득된다. 이것을 정제하지 않고 다음의 화합물(II)의 제조에 쓴다.190 g of compound of formula (XIII) and 250 g of sodium bicarbonate are added to 500 ml of piperidine. The solution is vigorously stirred at 150 ° C. in an oil bath to reflux and then cooled to room temperature. 1.5 liters of ether are added to the mixture, followed by addition of a solution of 40% caustic soda in 1 liter of water. The ether layer is separated and the aqueous layer is extracted with 500 ml of ether each time. The ether extracts are combined and dried over sodium sulfate and cleaned with activated carbon. Filter through "neolith" with suction filter and wash with ether. The liquid is concentrated in a rotary evaporator, which is first concentrated to 50 ° C. in a vacuum of a water jet pump and then to 100 ° C., whereby 180 g of oily compound (IIa) is obtained. It does not refine | purify this and uses for manufacture of the following compound (II).
실험식 : C6H25NO4 Experimental formula: C 6 H 25 NO 4
분자량 : 295.38Molecular Weight: 295.38
= +41.6℃(메탄올 중에서) = +41.6 ° C (in methanol)
실시예 1에서 기술한 방법과 동일하게 조작하여 다음표에서 표시된 구조식의 화합물을 얻는다. (표 1를 참조).The same procedure as described in Example 1 was carried out to obtain a compound of the structural formula shown in the following table. (See Table 1).
3-모르폴리노메틸-4-베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-((4,3,1,0,3,7)-데칸(XIII).3-morpholino-4-beta-hydroxy-8-methoxy-10-methylene -2,9- dioxa-tricyclo - ((4,3,1,0, 3,7) - decane (XIII ).
3-(4-메틸-1-피페라지닐메틸)-4-베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-((4,3,1,0,3,7)-데칸(XIV).3- (4-Methyl-1-piperazinylmethyl) -4-beta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo-((4,3,1,0, 3,7 ) -decane (XIV).
3-피로리디노메틸-4-베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-((4,3,1,0,3,7)-데칸(IV).3-fatigue Li dino-4-beta-hydroxy-8-methoxy-10-methylene -2,9- dioxa-tricyclo - ((4,3,1,0, 3,7) - decane (IV ).
3-(4-페닐-1-피페라지닐메틸)-4-베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-((4,3,1,0,3,7)-데칸(XIV).3- (4-phenyl-1-piperazinylmethyl) -4-beta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo-((4,3,1,0, 3,7 ) -decane (XIV).
3-(4-하이드록시에틸-1-피페라지닐메틸)-4-베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-((4,3,1,0,3,7)-데칸(XVII).3- (4-hydroxyethyl-1-piperazinylmethyl) -4-beta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo-((4,3,1, 0, 3,7 ) -decane (XVII).
3-(N,N',N''-트리에틸에틸렌디아미노메틸)-4-베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-((4,3,1,0,3,7)-데칸(XVIII).3- (N, N ', N''-triethylethylenediaminomethyl) -4-beta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo-((4,3 , 1,0, 3,7 ) -decane (XVIII).
3-(N-벤질-N-메틸아미노메틸)-4-베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-((4,3,1,0,3,7)-데칸(XIX).3- (N-benzyl-N-methylaminomethyl) -4-beta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo-((4,3,1,0, 3 , 7 ) -decane (XIX).
3-(N,N-디벤질이미노메틸)-4-베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-((4,3,1,0,3,7)-데칸(X X).3- (N, N-Dibenzyliminomethyl) -4-beta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo-((4,3,1,0, 3 , 7 ) -decane (XX).
3-(헥사메틸렌이미노메틸)-4-베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-((4,3,1,0,3,7)-데칸(XXI).3- (hexamethyleneiminomethyl) -4-beta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo-((4,3,1,0, 3,7 )- Deccan (XXI).
3-(1-인도리노메틸)-4-베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-((4,3,1,0,3,7)-데칸(XXII).3- (1-Indolinomethyl) -4-beta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo-((4,3,1,0, 3,7 )- Decane (XXII).
3-피페리디노메틸-4-옥소-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-((4,3,1,0,3,7)-데칸(XXIII).3-piperidino-methyl-4-oxo-8-methoxy-10-methylene -2,9- dioxa-tricyclo - ((4,3,1,0, 3,7) - decane (XXIII).
3-(N,N-디부틸아미노메틸)-4-베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-((4,3,1,0,3,7)-데칸(XXIV).3- (N, N-dibutylaminomethyl) -4-beta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo-((4,3,1,0, 3, 7 ) -decane (XXIV).
3-[4-(2-피리딜)-1-피페라지닐메틸]-4-베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-((4,3,1,0,3,7)-데칸(XXV).3- [4- (2-pyridyl) -1-piperazinylmethyl] -4-beta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo-((4,3 , 1,0, 3,7 ) -decane (XXV).
[표 1]TABLE 1
[실시예 2]Example 2
[구조식(vIII) 화합물로부터 구조식(XIII)의 3-모르폴리노메틸-4베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-((4,3,1,0,3,7)-데칸의 제법][3-morpholinomethyl-4beta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo-((4,3,1) of formula (XIII) , 0, 3,7 ) -making method of decane]
화합물(VIII) 38g 및 소듐요다이드 50g을 모르폴린 100ml에 가한다. 용액을 3시간 환류한 다음, 실온으로 냉각한다. 용매를 증발시킨후, 혼합물을 2N-염산 200ml로 처리하고 소량의 메탄올을 용매로서 가한다. 산성 및 중성 불순물을 제거하기 위해서 반응 용액을 각회 100ml의 에텔로 처음 2회 추출하여 에텔층을 버린다. 식염으로 포화시킨 수층에 2N-가성소다 용액을 가하고 마지막으로 각회 100ml의 에텔로 5. 추출한다. 이 염기성 에텔추출액을 황산소다상에서 건조하고 활성탄으로 깨끗이한후, "데오티트"를 통해 흡인 여과한다. 진공에서 농축하면, 이론량으로 61%인 유상 화합물(XIII)이 17.92g 수득된다.38 g of compound (VIII) and 50 g of sodium iodide are added to 100 ml of morpholine. The solution is refluxed for 3 hours and then cooled to room temperature. After evaporating the solvent, the mixture is treated with 200 ml of 2N hydrochloric acid and a small amount of methanol is added as solvent. In order to remove acidic and neutral impurities, the reaction solution is first extracted twice with 100 ml of ether each time to discard the ether layer. Add 2N caustic soda solution to the salt-saturated aqueous layer, and finally extract 5 times with 100 ml of ether. The basic ether extract is dried over sodium sulfate, washed with activated charcoal, and then suction filtered through “deo titite”. Concentration in vacuo afforded 17.92 g of 61% theoretical oily compound (XIII).
실험식 : C15H23NO5 Experimental formula: C 15 H 23 NO 5
분자량 : 297.35Molecular Weight: 297.35
= +42° (메탄올) = + 42 ° (methanol)
[실시예 3]Example 3
[화합물(VIII)로 부터 구조식(XXV)의 3-[4-(2-피리딜)-1-피페라지닐메틸]-4-베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-((4,3,1, 0,3,7)-데칸의 제법.][3- [4- (2-pyridyl) -1-piperazinylmethyl] -4-beta-hydroxy-8-methoxy-10-methylene-2 of formula (XXV) from compound (VIII), Preparation of 9-dioxatricyclo-((4,3,1, 0, 3,7 ) -decane.]
38g의 화합물(VIII)및 49g의 1-(2-피리딜)피페라진 및 50g의 탄소소다를 100ml의 디메틸포름아미드에 취하고 8시간 환류시킨다. 혼합물을 "데오리트"상에서 여과한 후, 메탄올로 세척하고, 여액을 진공하농축한다. 증발잔사를 200ml메탄올에 녹이고, 10ml물에 8g의 가성소다를 녹인 용액을 가한 다음, 혼합물을 10분간 실온에서 정치한다. 희-염산으로 중화한 다음, 용매를 증발시키고, 잔유물을 2N-가성소다 용액으로 알칼리성이 되게하고, 클로로포름으로 추출한다. 황산소다로 처리한후, 활성탄으로 처리하고, 클로로포름층을 "데오리트"로 흡인 여과한다. 클로로포름으로 증발하고 증발잔사를 실리카겔상에서 용매로 n-헥산과 50%에텔로 칼람 크로마토그라피한다. 용출액을 농축하고, 잔사를 메탄올에 녹인후, 결정화한다. 눗체(nutsche)상에서 여과한 후, 메탄올로 세척하면 백색 결정으로 다음 구조식의 화합물이 이론량 77.7%인 29.0g 수득된다.38 g of Compound (VIII) and 49 g of 1- (2-pyridyl) piperazine and 50 g of carbon soda are taken up in 100 ml of dimethylformamide and refluxed for 8 hours. The mixture is filtered over "deolith", washed with methanol and the filtrate is concentrated in vacuo. The evaporated residue is dissolved in 200 ml methanol, and a solution of 8 g of caustic soda is added to 10 ml of water, and then the mixture is allowed to stand at room temperature for 10 minutes. After neutralization with dilute hydrochloric acid, the solvent is evaporated and the residue is made alkaline with 2N-caustic soda solution and extracted with chloroform. After treatment with sodium sulfate, treatment with activated carbon, and the chloroform layer is suction filtered with "deodorite". Evaporate with chloroform and evaporate the residue on silica gel with n-hexane and 50% ether chromatography on silica gel. The eluate is concentrated, the residue is dissolved in methanol and crystallized. After filtration over nutsche and washing with methanol, white crystals yield 29.0 g of a compound of the following structural formula 77.7% in white crystals.
실험식 : C20H27N3O4 Experimental formula: C 20 H 27 N 3 O 4
분자량 : 373.45Molecular Weight: 373.45
융 점 : 130-132°Melting Point: 130-132 °
= 0°(메탄올) = 0 ° (methanol)
[실시예 4]Example 4
[구조식(VIII)의 화합물로부터 구조식(XXVI)의 3-(N,N-디에틸아미노메틸) -4-베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-((4,3,1,0 ,3,7)-데칸의 제법.][3- (N, N-diethylaminomethyl) -4-beta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo of formula (XXVI) from the compound of formula (VIII) -((4,3,1,0, 3,7 ) -Decane Preparation.]
38g의 화합물(VIII) 및 50g의 중조를 200ml 디에틸아민에 취하고, 용액을 유욕중에서 봄브관(bomb tube)내에서 150℃로 6시간 정치 한다음, 물 10ml에 4g의 가성소다를 녹인용액 및 100ml의 메탄올을 가한다. 10분간 실온에서 정치한 후, 혼합물을 6ml초산으로 처리한다. 용매를 증발시킨후, 100ml에테르를 가하고, 혼합물을 물 200ml에 녹인다음, 30%가성소다 용액 40ml를 혼화하고, 교반한다. 에텔층을 제거하고, 수층을 각회 100ml에텔로 3회 추출한다. 층을 합하고, 황산소다상에서 건조하고, 활성탄으로 탈색한다. "데오리트"로 흡인 여과하고 에텔로 세척한 다음, 여액을 농축하는데 처음은 물 제트 펌프(jet pum)의 진공에서 50℃로 다음은 회전 증발기에서 오일 펌프진공으로 100℃에서 농축한다. 다음 구조식(XXVI)의 유상물질 32g이 수득된다.38 g of compound (VIII) and 50 g of sodium bicarbonate were taken up in 200 ml of diethylamine, the solution was allowed to stand at 150 ° C. for 6 hours in a bomb tube in an oil bath, and 4 g of sodium hydroxide was dissolved in 10 ml of water. 100 ml of methanol is added. After standing at room temperature for 10 minutes, the mixture is treated with 6 ml acetic acid. After evaporating the solvent, 100 ml ether is added, the mixture is dissolved in 200 ml of water, 40 ml of 30% caustic soda solution is mixed and stirred. The ether layer is removed and the aqueous layer is extracted three times with 100 ml ether each time. The layers are combined, dried over sodium sulfate and bleached with activated charcoal. Suction filtration with “deodorite” and washing with ether, then concentrated the filtrate first at 50 ° C. in a vacuum of a water jet pump and then at 100 ° C. with an oil pump vacuum in a rotary evaporator. 32 g of an oily substance of the following structural formula (XXVI) are obtained.
실험식 : C15H25NO4 Experimental formula: C 15 H 25 NO 4
분자량 : 283.37Molecular Weight: 283.37
= +48°(메탄올) = + 48 ° (methanol)
실시예 4와 동일한 방법에 의해 다음의 화합물이 생성된다. 3-요도메틸-4-옥소-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-((4,3,1,0,3,7)-데칸에서 구조식 3-(N,N-디에틸아미노메틸)-4-옥소-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-((4,3,1,0,3,7)-데칸의 제법.By the same method as in Example 4, the following compounds were produced. 3-urethra-methyl-4-oxo-8-methoxy-10-methylene -2,9- dioxa-tricyclo - ((4,3,1,0, 3,7) decane in formula 3- (N, N- diethylamino) -4-oxo-8-methoxy-10-methylene -2,9- dioxa-tricyclo - ((4,3,1,0, 3,7) the preparation of decane.
실험식 : C15H23NO4 Experimental formula: C 15 H 23 NO 4
분자량 : 281.34Molecular Weight: 281.34
3-요도메틸-4-알파-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-((4,3,1,0,3,7)-데칸에서 3-(N,N-디에틸아미노메틸)-4-알파 -하이드록시 -8-메톡시-10-메틸렌-2,9-디옥사트리시클로-((4,3,1,0,3,7)-데칸(XXVIII)의 제법.3-methyl-4-urethral alpha-hydroxy-8-methoxy-10-methylene -2,9- dioxa-tricyclo - ((4,3,1,0, 3,7) - decane-3-in ( N, N-diethylaminomethyl) -4-alpha-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo-((4,3,1,0, 3,7 )- The preparation of decane (XXVIII).
실험식 : C15H25NO4 Experimental formula: C 15 H 25 NO 4
분자량 : 283.36Molecular Weight: 283.36
[실시예 5]Example 5
[화합물(IIa)에서 3-피페리디노메틸-4-베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-((4,3,1,0,3,7)-데칸의 제법.][Compound (IIa) 3- piperidino-4-beta-hydroxy-8-methoxy-10-methylene -2,9- dioxa-tricyclo - ((4,3,1,0, 3, 7 ) -The recipe of decane.]
수첨분해용장치에 처음 10분간 질소를 도입하고 다음 10분간은 수소를 도입하여 수소로 가득차게 한다.Nitrogen is introduced into the hydrocracking system for the first 10 minutes and hydrogen is introduced for the next 10 minutes to fill with hydrogen.
100g의 뎀프 라니 닉켈(damp Raney nickel)을 장치의 수첨분해 플라스크에 도입하고, 메탄올로 세척한 다음 약 2분간 교반하면서 실온에서 약한 게이지 압력(gauge pressure)으로 일차적 수첨분해를 행한다. 메탄올 250ml 중의 화합물(IIa) 180g이 용해된 용액을 플라스크에 도입시킨후 소량의 물에 가성소다 20g을 용해시킨 용액을 첨가하고 실온으로 냉각한 후, 메탄올로 희석하고 다시 실온으로 냉각한다. 교반하면서, 약산의 게이지 압력하 반응 요액을 약30분간 실온에서 수첨 분해한다. 수소 흡수가 끝나는 즉시, 혼합물을 "데오리트"상에서 흡인 여과한다음, 메탄올로 세척한다. (주의 : 촉매는 화상위험이 있으므로 절대 건조되지 않도록 한다.)100 g of damp Raney nickel is introduced into the hydrocracking flask of the device, washed with methanol and subjected to primary hydrocracking at a slight gauge pressure at room temperature with stirring for about 2 minutes. A solution in which 180 g of compound (IIa) in 250 ml of methanol was dissolved was introduced into a flask. A solution of 20 g of caustic soda in a small amount of water was added thereto, cooled to room temperature, diluted with methanol, and cooled to room temperature again. While stirring, the reaction urine is subjected to hydrolysis at room temperature for about 30 minutes under gauge pressure of a weak acid. As soon as the hydrogen uptake is over, the mixture is suction filtered on sdeortite and then washed with methanol. (Caution: Do not dry catalyst as it may cause burns.)
30ml의 초산을 가한후, 혼합물을 60℃에서 증발하다, 실온으로 냉각한다. 잔사를 에텔에 취하고 실리카겔 250ml로 페이스트로 만든다(입자크기 0.2-0.5mm).After addition of 30 ml of acetic acid, the mixture is evaporated at 60 ° C. and cooled to room temperature. The residue is taken up in ether, and paste into 250 ml of silica gel (particle size 0.2-0.5 mm).
50℃에서 용매를 증발한 후, 잔유물을 n-헥산에 취하고 60℃에서 농축한다. 이 잔유물을 500g의 실리카겔상 칼람(입자크기 0.2-0.5mm)내에서 여과하는데, 처음에는 n-헥산(1리터)로 그 다음에는 n-헥산중의 1.5%디에틸아민으로 여과한다.After evaporating the solvent at 50 ° C., the residue is taken up in n-hexane and concentrated at 60 ° C. The residue is filtered in 500 g of silica gel column (particle size 0.2-0.5 mm), first with n-hexane (1 liter) and then with 1.5% diethylamine in n-hexane.
여액을 60℃에서 증발하면, 유상의 화합물(II) 150g이 수득된다.When the filtrate is evaporated at 60 ° C., 150 g of oily compound (II) is obtained.
실험식 : C16H27NO4 Experimental formula: C 16 H 27 NO 4
분자량 : 297.399Molecular Weight: 297.399
= 0°(메탄올) = 0 ° (methanol)
실시예 5의 제법과 동일하게 조작하여 다음 기술하는 화합물을 얻었다. (표 2참조). 3-모르폴리노메틸-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-4,3,1,0,3,7-데칸(XXIX). (3-(4-메틸-1-피페라지닐메틸)-4-베타-하이드록시-8-메톡시-10-메톡-2,9-디옥사트리시클로-4,3,1,0,3,7-데칸(XXX). 3-피로리디노메틸-4-베타-하이드록시-8-알파-메톡시-10-알파-메틸-2,9-디옥사트리시클로-4,3,1,0,3,7-데칸(XXXI).In the same manner as in the manufacturing method of Example 5, the compound described below was obtained. (See Table 2). 3-morpholinomethyl-4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo-4,3,1,0, 3,7 -decane (XXIX). (3- (4-methyl-1-piperazinylmethyl) -4-beta-hydroxy-8-methoxy-10-methox-2,9-dioxatricyclo-4,3,1,0, 3 , 7 -decane (XXX) 3-Pyridinomethyl-4-beta-hydroxy-8-alpha-methoxy-10-alpha-methyl-2,9-dioxatricyclo-4,3,1, 0, 3,7 -decane (XXXI).
(3-(4-페닐-1-피페라지닐메틸)-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(XXXII)(3- (4-phenyl-1-piperazinylmethyl) -4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0, 3,7 ] -Decan (XXXII)
(3-(4-하이드록시에틸-1-피페라지닐메틸)-4-베타-하이드록시-8-메톡시-10-에틸-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(XXXIII)(3- (4-hydroxyethyl-1-piperazinylmethyl) -4-beta-hydroxy-8-methoxy-10-ethyl-2,9-dioxatricyclo- [4,3,1, 0, 3,7 ] -Decane (XXXIII)
-3-(N,N',N''-트리에틸에틸렌아미노메틸)-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-4,3,1,0,3,7-데칸(XXXIV)-3- (N, N ', N''-triethylethyleneaminomethyl) -4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo-4,3,1 , 0, 3,7 -decan (XXXIV)
3-(N-벤질-N-메틸아미노메틸)-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-4,3,1,0,3,7-데칸(XXXV)3- (N-benzyl-N-methylaminomethyl) -4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo-4,3,1,0, 3,7 Deccan (XXXV)
3-(N,N-디벤질아미노에틸)-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(XXXVI)3- (N, N-dibenzylaminoethyl) -4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0, 3,7 ] -Decan (XXXVI)
3-섬사메틸렌이미노에틸-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(XXXVII)3-methylene filament butylimino-ethyl-4-beta-hydroxy-8-methoxy-10-methyl -2,9- dioxa-tricyclo [4,3,1,0, 3,7] - decane (XXXVII )
3-(1-인돌리노메틸)-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(XXXVIII)3- (1-Indolinomethyl) -4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0, 3,7 ] -decane (XXXVIII)
3-4-(2-피리딜)-1-피페라지닐메틸-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(XXXIX)3-4- (2-pyridyl) -1-piperazinylmethyl-4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1, 0, 3,7 ] -Decan (XXXIX)
3-피로리디노메틸-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(XL)3-fatigue Li dino-4-beta-hydroxy-8-methoxy-10-methyl -2,9- dioxa-tricyclo [4,3,1,0, 3,7] - decane (XL)
3-피레리디노메틸-4-알파-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(XLI)3 Pirelli dino-4-alpha-hydroxy-8-methoxy-10-methyl -2,9- dioxa-tricyclo [4,3,1,0, 3,7] - decane (XLI)
3-클로로메틸-4-알파-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸에서부터.3-Chloro-4-alpha-hydroxy-8-methoxy-10-methyl -2,9- dioxa-tricyclo [4,3,1,0, 3,7] decane from.
3-(N,N-디부틸아미노메틸)-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-4,3,1,0,3,7-데칸(XLII)3- (N, N- dibutylamino) -4-beta-hydroxy-8-methoxy-10-methyl -2,9- dioxa-tricyclo -4,3,1,0, 3,7- Deccan (XLII)
3-(N,N-디에틸아미노메틸)-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-4,3,1,0,3,7-데칸(XLIII)3- (N, N- diethylamino) -4-beta-hydroxy-8-methoxy-10-methyl -2,9- dioxa-tricyclo -4,3,1,0, 3,7- Deccan (XLIII)
[표 2]TABLE 2
[실시예 6]Example 6
[3-(N-메틸 아미노메틸) -4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-4,3,1,0,3,7-데칸(XLIV)의 제법.][3- (N-methyl aminomethyl) -4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo-4,3,1,0, 3,7 -decane ( XLIV) recipe.]
16.9g의 3-(N-벤질-N-메틸아미노에틸)-4-베타-하이드록시-8-메톡시 -10-메틸-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(XXXV)를 에탄올에 녹이고 5.0g의 산화팔라듐 존재하 2시간 동안 수소로 수첨분해한다. 수소 흡수가 끝나는 즉시, 혼합물을 "데오리트"상에서 흡인 여과하고 에탄올로 세척한다. 여액을 농축한 후, 클로로포름/에텔로 결정화하면 이론향 84%에 상당하는 탈벤질화 화합물 11g이 생성된다. 결정물을 에텔로 세척하고 공기 건조한다.16.9 g 3- (N-benzyl-N-methylaminoethyl) -4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0 , 3,7 ] -decane (XXXV) is dissolved in ethanol and hydrolyzed with hydrogen for 2 hours in the presence of 5.0 g of palladium oxide. As soon as the hydrogen uptake is over, the mixture is suction filtered on sdeortite and washed with ethanol. The filtrate was concentrated and then crystallized with chloroform / ether to give 11 g of debenzylated compound corresponding to 84% of theory. The crystals are washed with ether and air dried.
실험식 : C12H21NO4+H2OExperimental formula: C 12 H 21 NO 4 + H 2 O
분자량 : 261.30Molecular Weight: 261.30
융 점 : 161-164℃Melting Point: 161-164 ℃
= 25°(메탄올) = 25 ° (methanol)
[실시예 7]Example 7
[화합물(II)로부터 3-피페리디노메틸-4-베타-페닐카르바모일옥시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[46,3,1,0,3,7]-데칸(XLV)의 제법.][3-Piperidinomethyl-4-beta-phenylcarbamoyloxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [46,3,1,0, from compound (II) 3,7 ] -The preparation of decane (XLV).]
5.0g의 화합물(II)를 10ml의 메틸렌클로라이드에 녹이고, 3ml의 페닐이소시아네이트 및 680mg의 페닐머큐릭 아세테이트를 촉매로서 첨가하고 혼합물을 1-2시간 환류시킨다. 5ml의 메탄올을 가한 후, 혼합물을 농축한다. 잔유물을 에텔에 녹이고, 황산소다 및 활성탄으로 처리한다.5.0 g of compound (II) is dissolved in 10 ml of methylene chloride, 3 ml of phenylisocyanate and 680 mg of phenylmercuric acetate are added as catalyst and the mixture is refluxed for 1-2 hours. After 5 ml of methanol is added, the mixture is concentrated. The residue is taken up in ether and treated with sodium sulfate and activated carbon.
여과 후, 에텔로 세척하고 증발시키면, 다음 구조식(XVL)의 결정형 페닐카르바메이트 6.27g이 얻어지는데, 이것은 이론량의 90%에 상당한다.After filtration, washing with ether and evaporation yielded 6.27 g of crystalline phenylcarbamate of the following structural formula (XVL), corresponding to 90% of theory.
실험식 : C23H32N2O5 Experimental formula: C 23 H 32 N 2 O 5
분자량 : 416.52Molecular Weight: 416.52
융 점 : 81-86℃Melting Point: 81-86 ℃
실시예 7과 동일한 방법으로 조작하여 다음의 화합물을 얻었다(표 3 참조).The following compound was obtained by operation in the same manner as in Example 7 (see Table 3).
3-헥사메틸렌이미노에틸-4-베타-에틸카르바모일옥시-8-메틸-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(XLVI)3-hexamethyleneiminoethyl-4-beta-ethylcarbamoyloxy-8-methyl-10-methylene-2,9-dioxatricyclo- [4,3,1,0, 3,7 ] -decane (XLVI)
3-[4-(P-클로로벤조하이드릴)-1-피레라지닐메틸]-4-베타-에틸카르바모일옥시-8-메틸-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(XLVII)3- [4- (P-chlorobenzohydryl) -1-pyrerazinylmethyl] -4-beta-ethylcarbamoyloxy-8-methyl-10-methylene-2,9-dioxatricyclo- [ 4,3,1,0, 3,7 ] -decane (XLVII)
3-[4-메틸-1-피레라지닐메틸]-4-베타-페닐카르바모일옥시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(XLVIII)3- [4-methyl-1-pyrerazinylmethyl] -4-beta-phenylcarbamoyloxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1, 0, 3,7 ] -decane (XLVIII)
3-[4-(2-에틸카르바모일옥시에틸)-1-피레라지닐메틸]-4-베타-에틸카르바모일옥시-8-메틸-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(XLIX)3- [4- (2-ethylcarbamoyloxyethyl) -1-pyrerazinylmethyl] -4-beta-ethylcarbamoyloxy-8-methyl-10-methylene-2,9-dioxatricyclo - [4,3,1,0, 3,7] - decane (XLIX)
3-[4(-피리딜-2)-1-피레라지닐메틸]-4-베타-에틸카르바모일옥시-8-메틸-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(L)3- [4 (-pyridyl-2) -1-pyrerazinylmethyl] -4-beta-ethylcarbamoyloxy-8-methyl-10-methylene-2,9-dioxatricyclo- [4, 3,1,0, 3,7 ] -decane (L)
3-(4-메틸-1-피레라지닐메틸)-4-베타-에틸카르바모일옥시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(LI)3- (4-methyl-1-pyrerazinylmethyl) -4-beta-ethylcarbamoyloxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1, 0, 3,7 ] -decane (LI)
3-(N,N',N''-트리에틸렌디아미노메틸)-4-베타-에틸카르바모일옥시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(LII)3- (N, N ', N''-triethylenediaminomethyl) -4-beta-ethylcarbamoyloxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4, 3,1,0, 3,7 ] -decane (LII)
3-피로리디노메틸-4-베타-이소프로필카르바모일옥시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(LIII)3-Pyridinomethyl-4-beta-isopropylcarbamoyloxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0, 3,7 ]- Deccan (LIII)
3-피페리디노메틸-4-알파-알킬카르바모일옥시-4,8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(LVI)3-piperidinomethyl-4-alpha-alkylcarbamoyloxy-4,8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0, 3,7 ] Deccan (LVI)
3-피페리디노메틸-4-알파-이소프로필카르바모일옥시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(LV)3-piperidinomethyl-4-alpha-isopropylcarbamoyloxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0, 3,7 ]- Deccan (LV)
3-피페리디노메틸-4-베타-에틸카르바모일옥시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(LVI)3-piperidinomethyl-4-beta-ethylcarbamoyloxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0, 3,7 ] -decane (LVI)
3-피로리디노메틸-4-베타-이소프로필카르바모일옥시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(LVII)3-Pyridinomethyl-4-beta-isopropylcarbamoyloxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0, 3,7 ]- Deccan (LVII)
3-(N,N-디에틸아미노에틸)-4-베타-알릴카르바모일옥시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(LVIII)3- (N, N-diethylaminoethyl) -4-beta-allylcarbamoyloxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0, 3,7 ] -decane (LVIII)
3-피페리디노메틸-4-베타-알릴카르바모일옥시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(LIX)3-piperidinomethyl-4-beta-allylcarbamoyloxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0, 3,7 ] -decane (LIX)
[표 3]TABLE 3
[실시예 8]Example 8
[구조식(V)에서 구조식(LX)의 3-모르폴리노메틸-4-베타-벤조일옥시-8-메톡시-10-메틸-2,9-디옥사이트리시클로,[4,3,1,0,3,7]-데칸의 제법][3-morpholinomethyl-4-beta-benzoyloxy-8-methoxy-10-methyl-2,9-dioxilicyclo of formula (LX) in formula (V), [4,3,1, 0, 3,7 ] -Decane's recipe]
3.75g의 화합물(V)를 15ml의 피리딘에 녹이고 부수 안식향상을 가한다. 혼합물은 2시간 동안 환류하고 클로로포름을 가한후 2-N-가성소다용액으로 진탕한다. 유기층을 물과 한번 세척하고 수층을 각회 클로로포름으로 2회 추출한다. 유기성추출물을 황산소다 및 활성탄으로 처리하고 "데오리트"상에서 여과한다.Dissolve 3.75 g of Compound (V) in 15 ml of pyridine and add ancillary benzoic enhancement. The mixture is refluxed for 2 hours, chloroform is added and then shaken with 2-N-caustic soda solution. The organic layer is washed once with water and the aqueous layer is extracted twice with chloroform each time. The organic extract is treated with sodium sulfate and activated charcoal and filtered over "deolite.
여액을 증발하고 잔류물을 실리칼겔중에서 용출재로서 50% 에텔-n-헥산을 사용하여 칼람크로마토 그라피한다. 용출액을 증발시키고 이소프로판올로 결정화하면 2.9g의 구조식(LX) 안식향산염이 얻어진다.The filtrate is evaporated and the residue is column chromatographed with 50% ether-n-hexane as eluent in silica gel. Evaporation of the eluate and crystallization with isopropanol yields 2.9 g of structural (LX) benzoate.
이론량 57%57% theory
실험식 : C22H29NO6 Experimental formula: C 22 H 29 NO 6
분자량 : 403.45Molecular Weight: 403.45
융 점 : 120-121℃Melting Point: 120-121 ℃
= +60°(메탄올중) = + 60 ° in methanol
실시예 8과 동일한 방법으로 조작하여 다음의 화합물을 얻는다.The following compounds were obtained in the same manner as in Example 8.
3-[4-(피리딜-2)-1-피레라지닐메틸]-4-베타-벤조일옥시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-(4,3,1,0,3,7)-데칸(LXI)3- [4- (pyridyl-2) -1-pyrerazinylmethyl] -4-beta-benzoyloxy-8-methoxy-10-methylene-2,9-dioxatricyclo- (4,3, 1,0, 3,7 ) -decane (LXI)
실험식 : C27H31N3O5 Experimental formula: C 27 H 31 N 3 O 5
분자량 : 477.54Molecular Weight: 477.54
3-(4-메틸-1-피레라지닐메틸)-4-베타-벤조일옥시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-(4,3,1,0,3,7)-데칸(LXII)3- (4-Methyl-1-pyrerazinylmethyl) -4-beta-benzoyloxy-8-methoxy-10-methylene-2,9-dioxatricyclo- (4,3,1,0, 3 , 7 ) -decane (LXII)
실험식 : C23H31N2O5 Experimental formula: C 23 H 31 N 2 O 5
분자량 : 416.09Molecular Weight: 416.09
융 점 : 99-102℃Melting Point: 99-102 ℃
3-[4-메틸-(2-벤조일옥시에틸)-1-피레라지닐메틸)-4-베타-벤조일옥시-8-메톡시-10-메틸-2,9-디옥사트리시클로-(4,3,1,0,3,7)-데칸(LXIII)3- [4-methyl- (2-benzoyloxyethyl) -1-pyrerazinylmethyl) -4-beta-benzoyloxy-8-methoxy-10-methyl-2,9-dioxatricyclo- (4 , 3,1,0, 3,7 ) -decane (LXIII)
실험식 : C31H38N2O7 Experimental formula: C 31 H 38 N 2 O 7
분자량 : 550.63Molecular Weight: 550.63
[실시예 9]Example 9
[3-헥사메틸린 이미노에틸 -4-베타-아세톡시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸에서 구조식(LXIV)의 3-헥사메틸린이미노 메틸-4-베타-아세톡시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,0,3,7] -데칸의 제법.][3-hexamethyl-lean-imino-ethyl-4-beta-acetoxy-8-methoxy-10-methyl -2,9- dioxa-tricyclo [4,3,1,0, 3,7] decane 3-hexamethyllinimino methyl-4-beta-acetoxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0,3 , 7 ] -The recipe of decane.]
3g의 3-헥사메틸린이미노 메틸-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸(XXXVII)를 6ml의 무수초산에 녹이고 용액을 30분간 실온에서 정치한다. 클로로포름을 가한 후, 혼합물을 2N-가성소다 용액으로 교반한다. 유기층을 물로 1회 세척하고 수층을 클로로포름으로 각 2회 추출한다. 유기성 추출물을 합하고, 황산소다 및 활성탄으로 처리한다. 흡인 여과하고 증발시 다음은 에텔만으로 그리고 마지막으로 에텔중의 10% 메탄올로 행한다. 용출물을 농축하면 이론량 67.8%의 구조식(LXIV)의 유상물질 2.2g이 수득된다.3 g of 3-hexamethyllinimino methyl-4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0, 3,7 ] -decane (XXXVII) is dissolved in 6 ml of acetic anhydride and the solution is left to stand at room temperature for 30 minutes. After adding chloroform, the mixture is stirred with 2N-caustic soda solution. The organic layer was washed once with water and the aqueous layer was extracted twice with chloroform. Organic extracts are combined and treated with sodium sulfate and activated carbon. Suction filtration and evaporation followed by ether only and finally with 10% methanol in ether. Concentration of the eluate gave 2.2 g of oily substance of the structural formula (LXIV) of 67.8% theory.
실험식 : C19H31NO5 Experimental formula: C 19 H 31 NO 5
분자량 : 337.44Molecular Weight: 337.44
= 0°(메탄올중) = 0 ° (in methanol)
[실시예 10]Example 10
[3-헥사메틸렌이미노 메틸-4-베타-프로피오닐옥시-8-메톡시-10-메틸-2.9-디옥사트리시클로-[4,3,1,03,7]데칸(LXV)의 제법]Of [3-hexamethyleneimino methyl-4-beta-propionyloxy-8-methoxy-10-methyl-2.9-dioxatricyclo- [4,3,1,0 3,7 ] decane (LXV) quite]
2.74g의 3-헥사 메틸렌이미노 메틸-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,03,7]데칸(XXXVII)을 6ml의 무수프로피온산에 녹이고 30분간 실온에서 정치한다. 클로로포름을 가한 후, 혼합물을 2N-가성소다 용액으로 교반하고 유기층을 황산소다 및 활상탄으로 처리한다. 유기층을 여과하고 농축한 후 이 소프로판올을 결정화하여 프로피온산염 950g을 얻는다. 이론량 29.4%2.74 g of 3-hexamethyleneimino methyl-4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0 3,7 ] decane ( XXXVII) is dissolved in 6 ml of propionic anhydride and left at room temperature for 30 minutes. After adding chloroform, the mixture is stirred with 2N-caustic soda solution and the organic layer is treated with sodium sulfate and charcoal. The organic layer is filtered and concentrated, and this isopropanol is crystallized to give 950 g of propionate. 29.4% of theoretical amount
실험식 : C20H33NO5 Experimental formula: C 20 H 33 NO 5
분자량 : 367.47Molecular Weight: 367.47
융 점 : 52-54℃Melting Point: 52-54 ℃
= 0°(메탄올중에서) = 0 ° (in methanol)
실시예 10에서 기술된 동일 방법에 의하여 다음 화합물을 생성한다.The following compound is produced by the same method described in Example 10.
3-[4-(P-클로로벤즈하이드릴)-1-피페라지닐 메틸]-4-베타-프로피오니옥시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로]4,3,1,03,7]-데칸(LXVI)3- [4- (P-chlorobenzhydryl) -1-piperazinyl methyl] -4-beta-propionioxy-8-methoxy-10-methylene-2,9-dioxatricyclo] 4, 3,1,0 3,7 ] -Decane (LXVI)
실험식 : C31H37N2ClO5 Experimental formula: C 31 H 37 N 2 ClO 5
분자량 : 552.78Molecular Weight: 552.78
[실시예 11]Example 11
[3-피페리디노 메틸-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로[4,3,1,03,7]-데칸(LXVII)의 염산염을 재법.]Of [3-piperidino methyl-4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo [4,3,1,0 3,7 ] -decane (LXVII) Hydrochloric acid method.]
고 이 5g의 화합물(Ⅱ)를 50ml에텔에 녹이고 건조 염화수소 가스를 침전 생성이 증지될때까지 용액에 통과시킨다. 에텔을 경사하여 따러내고 침전을 염화수소가 없는 에텔에 취하여 용해한다. 흡인 여과한 후 에텔로 세착하고 건조하면, 결정성 염산염 5.4g이 수득된다. 이론량의 97%에 상당한다.This 5 g of Compound (II) is dissolved in 50 ml of ether and the dry hydrogen chloride gas is passed through the solution until precipitation is formed. The ether is decanted off and the precipitate is taken up and dissolved in ether free of hydrogen chloride. After suction filtration, washing with ether and drying, 5.4 g of crystalline hydrochloride is obtained. It corresponds to 97% of theoretical amount.
실험식 : C16H28NClO4 Experimental formula: C 16 H 28 NClO 4
분자량 :33.86Molecular weight: 33.86
융 점 : 188℃Melting Point: 188 ℃
= 0°(메탄올중) = 0 ° (in methanol)
실시예 11에서 기술된 방법과 동일하게 조작하여 다음 화합물이 생성된다.(표 4 참조)Operation in the same manner as described in Example 11 yields the following compounds (see Table 4).
3-피롤리디노 메틸-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸염산염(LXVIII)3-Pyrrolidino Methyl-4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane hydrochloride (LXVIII)
3-모르폴리노 메틸-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸염산염((LXIX)3-morpholino methyl-4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane hydrochloride ((LXIX )
3-(4-페닐-1-피페라지닐 메틸-4-베타-하이드록시-8-메톡시-10-메틸 -2,9-디옥사트리시클로-[4,3,1,03,7]-데칸 디히드로클로라이드(LXX)3- (4-phenyl-1-piperazinyl methyl-4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -Decane dihydrochloride (LXX)
3-헥사메틸렌이미노 메틸-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸염산염ㅁ(LXXI)3-hexamethyleneimino methyl-4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane hydrochloride LXXI)
3-피페라지닐 메틸-4-베타-페닐카르바모일옥시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,03,7]데칸염산염(LXXII)3-piperazinyl methyl-4-beta-phenylcarbamoyloxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0 3,7 ] decane hydrochloride ( LXXII)
3-헥사메틸렌이미노메틸-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸염산염(LXXIII)3-hexamethylene-butylimino-4-beta-hydroxy-8-methoxy-10-methyl -2,9- dioxa-tricyclo [4,3,1,0, 3,7] decane hydrochloride ( LXXIII)
3-(1-인돌리노 메틸) -4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸염산염(LXXIV)3- (1-Indolinomethyl) -4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0, 3,7 ] -decane Hydrochloride (LXXIV)
3-인(1-인돌리노 메틸) -4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸염산염(LXXV)3-Phenyl (1-indolino methyl) -4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0, 3,7 ]- Decane Hydrochloride (LXXV)
3-[4-(P-클로로벤즈하이드릴)-1-피페라지닐메틸]-4-베타-에틸카르바모일옥시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸디히드로클로라이드(LXXVI)3- [4- (P-chlorobenzhydryl) -1-piperazinylmethyl] -4-beta-ethylcarbamoyloxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0, 3,7] decane dihydrochloride (LXXVI)
[실시예 12]Example 12
[화합물(IV)로부터 3-피로리디노 메틸-4-베타-하이드록시-8-메톡시-10 -메틸-2,9-디옥사트리시클로-[4,3,1,0,3,7]-데칸 하이드로젠 말레이네이트(LX XVII)의 제법.][From the compound (IV) 3- fatigue Li dino-4-beta-hydroxy-8-methoxy -10-methyl -2,9- dioxa-tricyclo [4,3,1,0, 3,7 ] -Preparation of Decane Hydrogen Maleate (LX XVII).]
구조식(IV)화합물 3.3g을 20ml의 에틸에 녹이고, 에텔중의 말레인산 1.4g의 용액을 가한다. 용매를 경사한 후, 잔유물을 에텔에 취하여 용해한다. 흡인 여과한 후 에텔로 세척한 후, 건조하여, 구조식(LXXII)의 말레이네이트 4.4g이 이론양으로 90.2% 수록된다.3.3 g of the compound of formula (IV) are dissolved in 20 ml of ethyl, and a solution of 1.4 g of maleic acid in ether is added. After decanting the solvent, the residue is taken up in ethane and dissolved. After suction filtration, washing with ether, and drying, 4.4 g of maleate of the formula (LXXII) contained 90.2% of theoretical amount.
실험식 : C19H27NO8 Experimental formula: C 19 H 27 NO 8
분자량 : 397.43Molecular Weight: 397.43
융 점 : 155-157℃Melting Point: 155-157 ℃
= +8°(메탄올중) = + 8 ° (in methanol)
실시예 12에 기술된 방법과 동일하게 조작하여 다음 화합물이 생성된다. (표 5 참조)Operation in the same manner as described in Example 12 yields the following compounds. (See Table 5)
3-(4-메틸-1-피페라지닐메틸)-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-(4,3,1,03,7)-데칸 디(하이드로젠 말레이네이트)(LXXVIII)3- (4-methyl-1-piperazinylmethyl) -4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- (4,3,1,0 3, 7 ) -decane di (hydrogen maleate) (LXXVIII)
3-피롤리디노 메틸-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-(4,3,1,03,7)-데칸 하이드로 말레이네이트(LXXIX)3-pyrrolidino methyl-4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- (4,3,1,0 3,7 ) -decane hydromaleate ( LXXIX)
3-[4(P-클로로벤즈하이드릴)-1-피페라지닐메틸]-4-베타-에틸카르바모일옥시-8-메톡시-메틸렌-2,9-디옥시-트리시클로-(4,3,1,03,7)-데칸 디(하이드로젠 말레이네이트)(LXXX)3- [4 (P-chlorobenzhydryl) -1-piperazinylmethyl] -4-beta-ethylcarbamoyloxy-8-methoxy-methylene-2,9-dioxy-tricyclo- (4 , 3,1,0 3,7 ) -decane di (hydrogen maleate) (LXXX)
3-(4-메틸-1-피페라지닐 메틸)-4-베타-페닐 카르바모일옥시-8-메톡시 -10-메틸렌-2,9-디옥사트리시클로-(4,3,1,03,7)-데칸 디(하이드로젠 말레이네이트)(LXXXI)3- (4-Methyl-1-piperazinyl methyl) -4-beta-phenyl carbamoyloxy-8-methoxy-10-methylene-2,9-dioxatricyclo- (4,3,1, 0 3,7 ) -decane di (hydrogen maleate) (LXXXI)
3-[4-(2-하이드록시에틸)-1-피페라지닐메틸]-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-(4,3,1,03,7)-데칸 디(하이드로젠 말레이네이트)(LXXII)3- [4- (2-hydroxyethyl) -1-piperazinylmethyl] -4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- (4,3 , 1,0 3,7 ) -decane di (hydrogen maleate) (LXXII)
[표 4]TABLE 4
[실시예 13]Example 13
[화합물(II)에서 부터 구조식(LXXXIII)의 3-피페리디노 메틸-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-(4,3,1,03,7)-데칸하이드로젠 타르트레이트의 제법.]3-Piperidino methyl-4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- (4,3,1 of formula (LXXXIII) from compound (II) , 0 3,7 ) -Decanhydrogen Tartrate Preparation.]
150g의 화합물(II)를 알코올 150ml에 녹이고 약 60℃에서 525.35ml의 에탄올에 미리 용해시킨 75.0g의 L(+)-주석산 용액을 가한다.150 g of compound (II) is dissolved in 150 ml of alcohol and 75.0 g of L (+)-tartrate solution, previously dissolved in 525.35 ml of ethanol at about 60 ° C., is added.
60℃에서 증탈시켜 최초로 투명한 용액으로 하여 구조식(II)의 하이드로젠 타르타레이트 결정으로 한다.The solution was evaporated at 60 ° C. to give a transparent solution for the first time to obtain hydrogen tartrate crystal of formula (II).
농축한 후, 결정을 에틸에 취한후, 흡인 여과하고 에텔로 세착한다.After concentration, the crystals are taken up in ethyl, suction filtered and washed with ether.
50℃에서 진공 건조한 다음, 구조식(LXXXIII)의 백색 결정형 하이드로젠 타르트레이트 203.6g이 수득된다. 이론량 91%After vacuum drying at 50 ° C., 203.6 g of white crystalline hydrogen tartrate of formula (LXXXIII) are obtained. 91% theory
실험식 : 분자량 : 447.46Experimental formula: Molecular weight: 447.46
융 점 : 178℃(케플러,보정안함)= -5.4°(물중)Melting Point: 178 ℃ (Kepler, No Compensation) = -5.4 ° (under water)
실시예 13과 동일하게 조작하여 다음의 화합물을 얻었다. (표 6 참조)In the same manner as in Example 13, the following compound was obtained. (See Table 6)
3-[4-(P-클로로벤즈 하이드릴)-1-피페라지닐 메틸]-4-베타-하이드록시 -8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸디(하이드로겐 타르트레이트)(LXXXIV)3- [4- (P-chlorobenz hydryl) -1-piperazinyl methyl] -4-beta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4, 3,1,0 3,7 ] -decane (hydrogen tartrate) (LXXXIV)
3-(4-(P-클로로벤즈 하이드릴)-1-피페라지닐 메틸)-4-베타-에틸카르바모일옥시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸디(하이드로젠 타르트레이트)(LXXXV)3- (4- (P-chlorobenz hydryl) -1-piperazinyl methyl) -4-beta-ethylcarbamoyloxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane (hydrogen tartrate) (LXXXV)
3-(4-(P-클로로벤즈하이드릴)-1-피페라지닐 메틸)-4-베타-프로피오닐옥시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-(4,3,1,03,7)-데칸디(하이드로젠 타르트레이트)(LXXXVI)3- (4- (P-chlorobenzhydryl) -1-piperazinyl methyl) -4-beta-propionyloxy-8-methoxy-10-methylene-2,9-dioxatricyclo- (4 , 3,1,0 3,7 ) -decane (hydrogen tartrate) (LXXXVI)
3-(4-(2-피리딜)-1-피페라지닐 메틸)-4-베타-벤조일옥시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-(4,3,1,03,7)-데칸트리(하이드로벤 타르트레이트)(LXXXVII)3- (4- (2-pyridyl) -1-piperazinyl methyl) -4-beta-benzoyloxy-8-methoxy-10-methylene-2,9-dioxatricyclo- (4,3, 1,0 3,7 ) -decantry (hydroben tartrate) (LXXXVII)
3-(4-메틸-1-피페라지닐 메틸)-4-베타-벤조일-옥시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸디(하이드로젠 타르트레이트)(LXX XVIII)3- (4-Methyl-1-piperazinyl methyl) -4-beta-benzoyl-oxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0 3 , 7 ] -decane (hydrogen tartrate) (LXX XVIII)
3-(4-(2-에틸카르바모일옥시에틸)-1-피페라지닐-메틸)-4-베타-카르바모일옥시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸(하이드로젠 타르트레이트)(LXXXIX)3- (4- (2-ethylcarbamoyloxyethyl) -1-piperazinyl-methyl) -4-beta-carbamoyloxy-8-methoxy-10-methylene-2,9-dioxatri Cyclo- [4,3,1,0 3,7 ] -decane (hydrogen tartrate) (LXXXIX)
3-(N,N',N"-트리에틸-에틸렌디아미노 메틸)-4-베타-에틸카르바모일옥시카-8-메톡시-10-메틸-2,9-디옥사 트리시클로-[4,3,1,03,7]-데칸디(하이드로젠타르트레이트)(XC)3- (N, N ', N'-triethyl-ethylenediamino methyl) -4-beta-ethylcarbamoyloxyca-8-methoxy-10-methyl-2,9-dioxa tricyclo- [ 4,3,1,0 3,7 ] -decanedi (hydrogen tartrate) (XC)
3-피페마다노메틸-4-알타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸 디(하이드로젠타르트레이트)(XCI)3-Pipemadanomethyl-4-alta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane di (hydrogen Tartrate) (XCI)
3-피페리디노 메틸-4-알파-이소프로필 카르바모일옥시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸디(하이드로벤 타르트레이트)(XCI I)3-piperidino methyl-4-alpha-isopropyl carbamoyloxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane Di (hydroben tartrate) (XCI I)
3-N,N-디메틸아미노 메틸-4-알파-하이드록-8-메톡시-10-메틸렌-2,9 -디옥사트리시클로-[4,3,1,03,7]-데칸 디(하이드로젠 타르트레이트)(XCIII)3-N, N-dimethylamino methyl-4-alpha-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane di (Hydrogen tartrate) (XCIII)
3-피페리다노 메틸-4-알파-알릴카르바모일옥시-8-메톡시-10-메틸-2,9 -디옥사트리시클로-[4,3,1,03,7]-데칸 하이드로젠 타르트레이트(XCIV)3-piperidano methyl-4-alpha-allylcarbamoyloxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane hydride Rosen tartrate (XCIV)
3-N,N-디에틸아미노메틸-4-알파-알릴 카로바모일옥시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸 하이드로젠 타르트레이트(XCV))3-N, N-diethylaminomethyl-4-alpha-allyl carovamoyloxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -Decane Hydrogen Tartrate (XCV))
3-N,N-디에틸아미노 메틸-4-옥소-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸 하이드로젠타르트레이트(XCVI)3-N, N-diethylamino methyl-4-oxo-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane hydrogentart Rate (XCVI)
3-모르폴리노메틸-4-베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸 하이드로젠 타르트레이트(XCVII)3-morpholinomethyl-4-beta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane hydrogen tartrate (XCVII)
3-피페리디노 메틸-4-베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸 하이드로젠 타르트레이트(XCVIII)3-piperidino methyl-4-beta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane hydrogen tartrate (XCVIII)
3-피롤리다노 메틸-4-베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸 하이드로젠 타르트레이트(XCIX)3-pyrrolidano methyl-4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane hydrogen tartrate (XCIX)
3-N,N-디부틸아미노메틸-4-베타-하이드록시-8-메톡시-10-메틸-2,9 -디옥사트리시클로-[4,3,1,03,7]-데칸 하이드로 젠타르트레이트(c)3-N, N-dibutylaminomethyl-4-beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane Hydrogentartrate (c)
[표 5]TABLE 5
[표 6]TABLE 6
[실시예 14]Example 14
[구조식(VIII)의 3-요도메틸-4-베타-아세톡시-8-메톡시-10-메틸렌-2, 9-디옥사트리시클로[4,3,1,03,7]-데칸에서 구조식(CIII)의 3-아미노메틸-4-메톡시 -10-메틸렌-2,9-디옥사트리시클로[4,3,1,03,7]-데칸의 제법.]In 3-iodomethyl-4-beta-acetoxy-8-methoxy-10-methylene-2, 9-dioxatricyclo [4,3,1,0 3,7 ] -decane of formula (VIII) Preparation of 3-aminomethyl-4-methoxy-10-methylene-2,9-dioxatricyclo [4,3,1,0 3,7 ] -decane of formula (CIII).]
a) 구조식(VIII)의 3-요도 메틸-4-베타-아세톡시-8-메톡시-10-메틸렌-2,9-디옥사 트리시클로[4,3,1,03,7]-데칸에서 구조식(CI)의 3-아지도메틸 -4-베타 -아세톡시-8-메틸시-10-메톡렌-2,9-디옥사트리시클로-4,3,1,03,7]-데칸의 제법a) 3-ureomethyl-4-beta-acetoxy-8-methoxy-10-methylene-2,9-dioxa tricyclo [4,3,1,0 3,7 ] -decane of formula (VIII) 3-Azidomethyl-4-beta-acetoxy-8-methylcy-10-methylene-2,9-dioxatricyclo-4,3,1,0 3,7 ]- Deccan Recipe
구조식(VIII)화합물 14g을 10㎖.의 헥사메틸인산아미드에 녹이고 30g의 소듐아자이드를 가한다. 혼합물을 맹렬히 교반하면서 4시간 동안 100℃로 가열한다. 600㎖의 에텔을 가한 다음 유기층을 각회 150㎖의 물로 5회 세척한다. 수층을 모아서 에텔로 흔들고 유기층을 합한 다음 황산소다상에서 건조한다.14 g of the compound of formula (VIII) is dissolved in 10 ml of hexamethyl phosphate amide and 30 g of sodium azide are added. The mixture is heated to 100 ° C. for 4 hours with vigorous stirring. 600 ml of ether are added and the organic layer is washed five times with 150 ml of water each time. The aqueous layers are combined, shaken with ether, the organic layers combined, and dried over sodium sulfate.
여별한후 잔여물을 에텔로 세척하고 여액윽 회전 층탈기에서 50℃로 농축하면 구조식(CI)의 무색 유상물질 11.5g을 얻는다.After filtration, the residue was washed with ether and concentrated to 50 ° C. in a filtrate rotary bed degasser to yield 11.5 g of a colorless oily substance of formula (CI).
실험식 : C13H17O5N3 Experimental formula: C 13 H 17 O 5 N 3
분자량 : 295.33Molecular Weight: 295.33
= -57°(메탄올) = -57 ° (methanol)
b) 구조식(CI)의 3-아지도메틸-4베타-아세톡시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로[4,3,1,03,7]-데칸에서 구조식(CII)의 3-아지도메틸-4메타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸의 제법b) 3-azidomethyl-4beta-acetoxy-8-methoxy-10-methylene-2,9-dioxatricyclo [4,3,1,0 3,7 ] -decane of formula (CI) 3-azidomethyl-4meth-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane of the formula (CII) in Recipe
10.55g의 3-아지도 메틸-4베타-아세톡시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로[4,3,1,03,7]-데칸을 250ml의 에텔에 녹이고 70ml의 메탄올 중의 1.5g 가성소다 용액을 가한다. 혼합용액을 실온에서 1시간 교반한 다음 빙초산으로 pH7로 조정하고 물 제트 펌프의 진공에서 농축한다, 잔사를 물에 취하고 수층을 황산암모니아로 염색하고 에텔로 수축한다. 합한 유기층을 황산소다 상에서 건조하고 여과한 후 회전증발기에서 50℃로 농축하면 구조식(II)의 무색 유상물질 7.9g이 수득되는데 이것은 이론량의 87.2%에 상당한다.10.55 g of 3-azido methyl-4beta-acetoxy-8-methoxy-10-methylene-2,9-dioxatricyclo [4,3,1,0 3,7 ] -decane 250 ml of ethyl Is dissolved in and a solution of 1.5 g caustic soda in 70 ml of methanol is added. The mixed solution is stirred at room temperature for 1 hour and then adjusted to pH 7 with glacial acetic acid and concentrated in vacuo on a water jet pump. The combined organic layers were dried over sodium sulfate, filtered and concentrated to 50 ° C. on a rotary evaporator to yield 7.9 g of a colorless oily substance of formula (II), corresponding to 87.2% of theory.
실험식 : C11H15N3O4 Experimental formula: C 11 H 15 N 3 O 4
분자량 : 253.26Molecular Weight: 253.26
= +10°(메탄올) = + 10 ° (methanol)
c)구조식(CII)의 3-아지도메틸-4베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로[4,3,1,03,7]-데칸에서 구조식(CII)의 3-아미노메틸-4베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸의 제법c) 3-azidomethyl-4beta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo [4,3,1,0 3,7 ] -decane of formula (CII) Of 3-aminomethyl-4beta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane of formula (CII) quite
구조식(CII)의 3-아지도 메틸-4베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로[4,3,1,03,7]-데칸 17.7g을 700ml의 메탄올에 녹이고 35ml의 80% 하이드라진 하이드레이트를 가한다.3-Azido methyl-4beta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo [4,3,1,0 3,7 ] -decane 17.7 g of formula (CII) Is dissolved in 700 ml of methanol and 35 ml of 80% hydrazine hydrate is added.
약 1g의 라니 닉켈을 도입하고 혼합물을 실온에서 1시간 동안 정치한다. 촉매를 아스베스트상에서 분리하고 여액을 50℃에서 물 제트 펌프의 진공중에서 농축한다. 잔사를 벤젠에 취하고, 여과하고 용매를 증발 제거한 후 에텔로 재결성하면 15.3g이 수득되는데 이것은 이론량의 94.6%에 해당한다.About 1 g of Raney Nickel is introduced and the mixture is allowed to stand at room temperature for 1 hour. The catalyst is separated on asbestos and the filtrate is concentrated in vacuo at a water jet pump at 50 ° C. The residue is taken up in benzene, filtered and the solvent is evaporated off and reconstituted with ethyl to give 15.3 g, which is 94.6% of theory.
[실시예 15]Example 15
[구조식(VIII)의 3-요도메틸-4 베타-아세톡시-8-메톡시-10-메틸렌-2,9-[4,3,1,03,7]-데칸에서 구조식(VI)의 3-아미노메틸-4메타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸의 제법.][Formula (VI) in 3-Udomethyl-4 beta-acetoxy-8-methoxy-10-methylene-2,9- [4,3,1,0 3,7 ] -decane of formula (VIII) Preparation of 3-Aminomethyl-4meth-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane.]
a) 구조식(VIII)의 3-요도메틸-4 베타-아세톡시-8-메톡시-10-메틸렌-2,9-디옥트리시클로-[4,3,1,03,7]-데칸에서 구조식(CIV)의 3-요도메틸-4베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로[4,3,1,03,7]데칸의 제법.a) in 3-iodomethyl-4 beta-acetoxy-8-methoxy-10-methylene-2,9-diotritricyclo- [4,3,1,0 3,7 ] -decane of formula (VIII) Preparation of 3-iodomethyl-4beta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo [4,3,1,0 3,7 ] decane of formula (CIV).
250ml 메탄올 중 화합물(VIII) 38.0g을 용해한 용액을 메탄올 50ml중 가성소다 4.0g을 용해한 용액을 가하고, 혼합물을 실온에서 30분간 교반한다. 500ml의 물을 가한후, 빙초산으로 중화한다. 황산암모니아를 가하여 포화시키고 에텔로 추출한다. 황산소다에서 건조한 후 잔사를 에텔로 세척하고 유시층을 합하여 진공에서 50℃로 농축하면 무색 유상물질 36.64g이 수득된다. 이론상 94.5%A solution in which 38.0 g of compound (VIII) was dissolved in 250 ml of methanol was added to a solution of 4.0 g of caustic soda in 50 ml of methanol, and the mixture was stirred at room temperature for 30 minutes. 500 ml of water is added and then neutralized with glacial acetic acid. Ammonia sulfate is added, saturated and extracted with ether. After drying over sodium sulfate, the residue was washed with ether and the oily layers were combined and concentrated to 50 ° C. in vacuo to give 36.64 g of a colorless oil. Theoretical 94.5%
b)구조식(CIV)의 3-요도메틸-4베타-하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸에서 구조식(CV)의-3-요도메틸-4베타 -하이드록시-8-메톡시-10-메틸렌-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸의 제법.b) 3-iodomethyl-4beta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane of formula (CIV) 3-Iodomethyl-4beta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane of formula (CV) Recipe.
에탄올 250ml중 구조식(CIV)의 3-요도메틸-4베타-하이드록시-8-메톡시 -10-메틸렌-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸 75g 용액에 에탄올 100ml 중 풀라티늄(IV) 옥사이드 6g 용액을 가하고 실온(수소 흡수량 5ℓ)에서 수첨분해시킨다. 촉매를 분리 제거하고 회전 증발기에서 50℃로 농축한다. 잔사를 실리카겔 상에서 n-헥산-에텔로 정제한 다음 n-헥산-에텔로 부터 재결정한다. 수율 : 69.9g, 이론량의 92.8%3-Iodomethyl-4beta-hydroxy-8-methoxy-10-methylene-2,9-dioxatricyclo- [4,3,1,0 3,7 ]-of formula (CIV) in 250 ml of ethanol. To a 75 g solution of decane, a 6 g solution of pulatin (IV) oxide in 100 ml of ethanol was added and hydrolyzed at room temperature (5 L of hydrogen uptake). The catalyst is separated off and concentrated to 50 ° C. on a rotary evaporator. The residue is purified by n-hexane-ether on silica gel and then recrystallized from n-hexane-ether. Yield: 69.9 g, 92.8% of theory
c) 구조식(CV)의 3-요도메틸-4베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸에서 구조식(CVI)의 3-요오메틸-4-메타 -아세톡시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸의 제법c) 3-iodomethyl-4beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane of formula (CV) 3-Iomethyl-4-meth-acetoxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane of formula (CVI) in Recipe
구조식(CV)의 3-요도메틸-4베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸 20g을 20ml 피리딘 및 10ml의 무수초산에 녹이고 한시간 동안 실온에서 정지한다. 반응 혼합물을 건조할때까지 에탄올로 반복 증발시킨다. 실리카켈상에서 n-핵산-에텔로 정제하면 목적 화합물(CVI)15.4g이 수득왼다. 이론량 68.5%20 g of 3 -yodomethyl-4beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane of the formula (CV) Dissolve in 20 ml pyridine and 10 ml acetic anhydride and stop at room temperature for one hour. The reaction mixture is repeatedly evaporated with ethanol until dry. Purification with n-nucleic acid-ether on silica gel yields 15.4 g of the target compound (CVI). 68.5% theoretical
d) 3-요도메틸-4베타-아세톡시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸(CVI)에서 3-아지도메틸-4베타-아세톡시-8-메톡시-10-메틸-2,6-디옥사트리시클로-[4,3,1,03,7]-데칸(CVII)의 제조d) 3- in 3-iodomethyl-4beta-acetoxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane (CVI) Preparation of azidomethyl-4beta-acetoxy-8-methoxy-10-methyl-2,6-dioxatricyclo- [4,3,1,0 3,7 ] -decane (CVII)
3-요도메틸-4-베타-아세톡시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[7,3,1,,03,7]데칸(CVI)에서 15.4g을 100ml의 핵사메틸인산 트리아미드에 녹이고 31g의 소듐아자이드를 가한다.15.4 g in 3-iodomethyl-4-beta-acetoxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [7,3,1,, 0 3,7 ] decane (CVI) Is dissolved in 100 ml of nucleated methylphosphate triamide and 31 g of sodium azide are added.
혼합물을 한시간 동안 100℃에서 교반하고 600ml의 에텔을 도입하고 각회 150ml의 에텔로 5회 추출한다. 수층을 에텔로 2회 추출하고 유시층을 모아서 황산소다상에서 건조한 다음 여과하고 진공에서 50℃로 넝축한다. 무색 유상물질(CVII) 12.0g을 얻는다. 이론량 100%.The mixture is stirred for one hour at 100 ° C., 600 ml of ether are introduced and extracted five times with 150 ml of ether each time. The aqueous layer was extracted twice with ether, and the aqueous layer was collected, dried over sodium sulfate, filtered and reduced to 50 ° C in vacuo. 12.0 g of colorless oil (CVII) are obtained. 100% of theoretical amount.
e) 구조식(CVII)의 3-아지도메틸-4베타-아세톡시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸에서 구조식(CVIII)의 3-아지도메틸-4베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸의 제법.e) 3-azidomethyl-4beta-acetoxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0 3,7 ]-of the formula (CVII)- 3-azidomethyl-4beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0 3,7 ]-of the formula (CVIII) in decane. Deccan recipe.
메탄올 20ml중의 가성소다 1.5g 용애을 에텔 200ml중의 12g의 3-아지 도메틸-4베타-아세톡시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸(CVII)의 용액에 가한다. 혼합 용액을 실온에서 10분간 교반하고 빙수 200ml로 도입시킨 다음 빙초산으로 중화한 후, 황산 암모니아로 포화시킨다.에텔로 추출한 후, 유기층을 합하고, 황산소다 상에서 건조하고 여과한 후 진공에서 농축한다. 이론량100%에 해당하는 무색유상(CVIII)이 10.7g 수득된다.12 g 3-azidomethyl-4beta-acetoxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1 in 1.5 g caustic soda in 20 ml of methanol , 0 3,7 ] -decane (CVII) is added to the solution. The mixed solution is stirred at room temperature for 10 minutes, introduced into 200 ml of ice water, neutralized with glacial acetic acid and saturated with ammonia sulfate. After extraction with ether, the organic layers are combined, dried over sodium sulfate, filtered and concentrated in vacuo. 10.7 g of colorless oil (CVIII) corresponding to a theoretical amount of 100% is obtained.
f) 3-아지도메틸-4베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸(CVIII)에서 3-아미노메틸-4베타-하이드록시-8-메틸시 -10-메틸-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸(VI)의 제법.f) in 3-azidomethyl-4beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane (CVIII) Preparation of 3-Aminomethyl-4beta-hydroxy-8-methylcy-10-methyl-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane (VI).
32ml의 하아드라진 하이드레이트(약 80%)을 10.7g의 3-아지도메틸 -4베타 -하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸(CVIII)의 용액에 가한다.32 ml of haadazine hydrate (approximately 80%) was added to 10.7 g of 3-azidomethyl-4beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1 , 0 3,7 ] -decane (CVIII) is added to the solution.
100ml 메탄올중의 약 1g의 라니 니켈용액을 가한후 혼합물을 실온에서 1시간 교반하다. 촉매를 여별하고 여액을 견조할때까지 진공에서 농축한다. 잔사를 물에 취하고 에텔로 추출하기 전에 가성소다로 알카리성으로 만든다, 에텔층을 합하고 황산소다상에서 건조한 후에 여과하고 40℃에서 진공으로 농축하면 무색 유상물질(VI)9.1g이 수득된다. 이론량 94.3%After adding about 1 g of Raney nickel solution in 100 ml methanol, the mixture was stirred at room temperature for 1 hour. The catalyst is filtered off and concentrated in vacuo until the filtrate is solid. The residue is taken up in water and made alkaline with caustic soda before extraction with ether, the ether layers combined, dried over sodium sulfate, filtered and concentrated in vacuo at 40 ° C. to give 9.1 g of colorless oil (VI). 94.3% theory
[실시예 16]Example 16
[3-아미노메틸-4베타-하이드록시-8-메톡시-10-메틸-2, 9-디옥사트리시클로-[4,3,1,03,7]-(VI)의 3-N,N, 디메틸아미노메틸-4메타-하이드록시-8-메틸시-10-메틸-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸(XI)의 제법.]3-N of [3-aminomethyl-4beta-hydroxy-8-methoxy-10-methyl-2, 9-dioxatricyclo- [4,3,1,0 3,7 ]-(VI) , N, Dimethylaminomethyl-4meth-hydroxy-8-methylcy-10-methyl-2,9-dioxatricyclo- [4,3,1,0 3,7 ] -decane (XI) .]
5ml (37%)포르마린 용액을 800mg의 3-아미노메틸-4베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸(VI)의 5ml 메탄올 용액을 가하고 실온에서 10분간 교반한다. 소량의 라니니켈을 가한후 실온에서 수첨 분해시킨다. 수소 흡수가 끝나는 즉시 촉매를 여별하고 여액을 건조시킨다. 실리카겔 상에서 클로로포름-메탄올로 정제하면 780mg의 화합물(XI)이 얻어진다. 이론량 : 86.9%5 ml (37%) formalin solution was added with 800 mg of 3-aminomethyl-4beta-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo- [4,3,1,0 3,7 ] 5 ml methanol solution of decane (VI) is added and stirred at room temperature for 10 minutes. A small amount of Ranickel is added and then hydrocracked at room temperature. As soon as hydrogen absorption is complete, the catalyst is filtered off and the filtrate is dried. Purification with chloroform-methanol on silica gel yields 780 mg of compound (XI). Theoretical amount: 86.9%
[실시예 17]Example 17
[3-요도메틸-4베타-아세톡시-8-메톡시-10-메틸-2, 9-디옥사트리시클로-[4,3,1,03,7]-데칸(VⅡ)에서 구조식(CXI)3-[1-아자비시클로(3,2,2,)-노나닐 ] -메틸-4베타-하이드록시-8-메틸시-10-메틸-2,9-디옥사트리시클로-[4,3,1,03,7] -데칸 하이드로젠 타르트레이트의 제법.]Structural formula in [ 3 -iodomethyl-4beta-acetoxy-8-methoxy-10-methyl-2, 9-dioxatricyclo- [4,3,1,0 3,7 ] -decane (VII) CXI) 3- [1-azabicyclo (3,2,2,)-nonanyl] -methyl-4beta-hydroxy-8-methylcy-10-methyl-2,9-dioxatricyclo- [4 , 3,1,0 3,7 ] -Decane Hydrogen Tartrate Preparation.]
7.6g의 화합물(VIII) 및 10g의 중조를 10ml의 디메틸 포름아미드에 취하고 7,5g의 3-아자비시클로-(3,2,2)노난을 가한다. 혼합물을 유욕에서 170℃로 비등시키고 실온으로 냉각한다. 농축한 후 40ml의 물 및 8ml의 30% 가성소다 용액을 잔유물에 가하고 각회 20ml의 에텔로 3회 추출한다. 에텔추출물을 농출하면 5.8g의 3-[1-아자비시클로-(3,2,2,)-노나닐]-메틸-4베타-하이드록시-8-메톡시-10-메틸-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸(CIX)가 얻어진다. 5.8g의 화합물(CIX)을 메탄올에 녹이고 4.0g의 라니 니켈 및 0.8g의 가성소다를 가한 후 수소로 수첨 분해한다. 수소흡수가 끝난는 즉시 혼합물을 "데오리트"상에서 흠인 여과하고 메탄올로 세척한다.7.6 g of compound (VIII) and 10 g of sodium bicarbonate are taken up in 10 ml of dimethyl formamide and 7,5 g of 3-azabicyclo- (3,2,2) nonane are added. The mixture is boiled to 170 ° C. in an oil bath and cooled to room temperature. After concentration, 40 ml of water and 8 ml of 30% caustic soda solution are added to the residue and extracted three times with 20 ml of ether each time. Concentration of the ether extract yields 5.8 g of 3- [1-azabicyclo- (3,2,2,)-nonanyl] -methyl-4beta-hydroxy-8-methoxy-10-methyl-2,9- Dioxatricyclo- [4,3,1,0 3,7 ] -decane (CIX) is obtained. Dissolve 5.8 g of compound (CIX) in methanol, add 4.0 g of Raney nickel and 0.8 g of caustic soda and hydrodecompose with hydrogen. Immediately after hydrogen sorption, the mixture is filtered over "deolite and washed with methanol.
여액에 1.2ml의 초산을 가한후, 용액을 농축하고 잔사를 에텔에 취하고, 실리카겔상(임자크기 0.2-0.5mm)에서 칼람크로마토그라피에 의해 정제한다. 용출 용매는 n-헥산 및 1.5% 디에틸아민이 적합하다. 용출액을 농축하며 4.4g의 결정형 3-[1-아자비시클로-(3,2,2,)-노나닐)메틸-4베타-하이드록시-8-메틸시-10-메틸-2,9-디옥사트리시클로-[4,3,1,03,7]-데칸(CXI)이 수득된다.After 1.2 ml of acetic acid was added to the filtrate, the solution was concentrated and the residue was taken up in ether, and purified by column chromatography on silica gel (minus size 0.2-0.5 mm). Elution solvents are suitable for n-hexane and 1.5% diethylamine. Concentrate the eluate and 4.4 g of crystalline 3- [1-azabicyclo- (3,2,2,)-nonanyl) methyl-4beta-hydroxy-8-methylcy-10-methyl-2,9-di Oxatricyclo- [4,3,1,0 3,7 ] -decane (CXI) is obtained.
4g의 화합물(CX)를 8ml의 에텔에 녹이고 1.94g의 L(+)-주석산의 13.6ml 에탄올 용액에 가한다.4 g of compound (CX) is dissolved in 8 ml of ether and added to a 13.6 ml ethanol solution of 1.94 g of L (+)-tartrate.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR7700414A KR810000612B1 (en) | 1977-02-23 | 1977-02-23 | Process for preparing 2,p-dioxatricyclo(4,3,1,0 3,7)decanes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR7700414A KR810000612B1 (en) | 1977-02-23 | 1977-02-23 | Process for preparing 2,p-dioxatricyclo(4,3,1,0 3,7)decanes |
Publications (1)
Publication Number | Publication Date |
---|---|
KR810000612B1 true KR810000612B1 (en) | 1981-06-07 |
Family
ID=19203916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR7700414A KR810000612B1 (en) | 1977-02-23 | 1977-02-23 | Process for preparing 2,p-dioxatricyclo(4,3,1,0 3,7)decanes |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR810000612B1 (en) |
-
1977
- 1977-02-23 KR KR7700414A patent/KR810000612B1/en active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2716146B2 (en) | Condensed indole derivative and method for producing the same | |
DE68920773T2 (en) | Quinolonecarboxylic acid derivatives. | |
JP3447292B2 (en) | Imidazopyridines and their use for the treatment of gastrointestinal diseases | |
US4904676A (en) | Amino-oxazole compounds having dopaminergic activity | |
US4954642A (en) | Forskolin compounds | |
DD283394A5 (en) | METHOD FOR THE PRODUCTION OF INDILOCARBAZOL DERIVATIVES | |
EP0648771A1 (en) | Galanthamine derivatives, a process for their preparation and their use as medicaments | |
PL96888B1 (en) | THE METHOD OF MAKING NEW BENZYLOAMINES | |
RU2284325C2 (en) | Derivatives of phenyl-3-aminomethylquinolone-2 as inhibitors of no-synthase, method for their preparing, biologically active compounds and pharmaceutical composition based on thereof | |
DE69318920T2 (en) | Ellipticine derivatives with anti-tumor effects | |
GB1571781A (en) | Pyridobenzodiazepines | |
KR810000612B1 (en) | Process for preparing 2,p-dioxatricyclo(4,3,1,0 3,7)decanes | |
EP0376624B1 (en) | 4,5,6,7-Tetrahydrobenzimidazole derivatives and their preparation | |
US4163055A (en) | 2,9-Dioxatricyclo[4,3,1,03,7 ] decane derivatives and pharmaceutical compositions thereof | |
DE2737630C2 (en) | ||
IE46908B1 (en) | Pyridobenzodiazepines | |
IE53463B1 (en) | Mono-and bisquaternary ammonium derivatives of 2 beta,16 beta-d-amino-5 alpha-androstane derivatives and pharmaceutical preparations containing same | |
US4824836A (en) | Spiro (4,5) decone compounds | |
DE1720033A1 (en) | New indole derivatives and processes for their preparation | |
DE69018335T2 (en) | Imidazoquinolone derivatives. | |
DE69006366T2 (en) | BENZO [b] PHENANTHROLINE DERIVATIVES, THEIR PRODUCTION AND THEIR THERAPEUTIC USE. | |
DE1959400A1 (en) | Process for the production of new azepine derivatives | |
US4207331A (en) | 2,9-Dioxatricyclo[4,3,1,03,7 ]decane derivatives and pharmaceutical compositions thereof | |
GB2142625A (en) | Piperazino-quinazolines | |
CZ280490A3 (en) | Pyridobenzoindole derivatives, process of their preparation and a pharmaceutical containing thereof |